SCHEMBL10189718

SCHEMBL10189718

COc1ccc(-c2[nH]nnc2-c2ccc(C)c(OC)c2OC)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
SCN4A P35499 1/20 0.38
MEN1 O00255 3/20 0.36
GFER P55789 1/20 0.36
MAPT P10636 2/20 0.36
GAA P10253 2/20 0.36
HSP90AA1 P07900 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ALPL P05186 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.36
ALOX12 P18054 1/20 0.36
XDH P47989 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411183 0.86 KMT2A (0.42) KMT2AMEN1MAPTKDM4EALDH1A1
SCHEMBL412624 0.77 TUBB4A (0.46) KMT2AMAPTKDM4EALDH1A1HPGD
SCHEMBL411907 0.76 GSK3A (0.43) KMT2ASCN4AMEN1MAPTKDM4E
SCHEMBL411571 0.75 KMT2A (0.44) KMT2AMEN1GFERMAPTKDM4E
SCHEMBL411698 0.75 TUBB4A (0.56) KMT2AMEN1MAPTKDM4EALDH1A1
SCHEMBL27630956 0.74 TEK (0.46) KMT2AMEN1MAPTHSP90AA1KDM4E
SCHEMBL411388 0.74 TUBB4A (0.54) KMT2AMEN1MAPTKDM4EALDH1A1
SCHEMBL411565 0.73 SMPD3 (0.40) KMT2AMEN1GAAALDH1A1HPGD
SCHEMBL4874569 0.73 FYN (0.42) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL4827003 0.73 MAPT (0.45) KMT2AMEN1GFERMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 KMT2A 2808/4885SCN4A 3595/4885MEN1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.